DK1106612T3 - Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase - Google Patents

Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase

Info

Publication number
DK1106612T3
DK1106612T3 DK00309627T DK00309627T DK1106612T3 DK 1106612 T3 DK1106612 T3 DK 1106612T3 DK 00309627 T DK00309627 T DK 00309627T DK 00309627 T DK00309627 T DK 00309627T DK 1106612 T3 DK1106612 T3 DK 1106612T3
Authority
DK
Denmark
Prior art keywords
protein transferase
farnesyl protein
compounds
derivatives useful
quinoline derivatives
Prior art date
Application number
DK00309627T
Other languages
Danish (da)
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1106612T3 publication Critical patent/DK1106612T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00309627T 1999-11-30 2000-11-01 Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase DK1106612T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16820799P 1999-11-30 1999-11-30
US17011999P 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
DK1106612T3 true DK1106612T3 (da) 2004-05-17

Family

ID=26863889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00309627T DK1106612T3 (da) 1999-11-30 2000-11-01 Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase

Country Status (12)

Country Link
US (1) US6596735B1 (de)
EP (1) EP1106612B1 (de)
JP (1) JP2001213876A (de)
AT (1) ATE259365T1 (de)
BR (1) BR0005633A (de)
CA (1) CA2327026A1 (de)
DE (1) DE60008206T2 (de)
DK (1) DK1106612T3 (de)
ES (1) ES2212971T3 (de)
MX (1) MXPA00011856A (de)
PT (1) PT1106612E (de)
TR (1) TR200400342T4 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
EP1322635B1 (de) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
MXPA05006676A (es) 2002-12-19 2005-08-16 Pfizer Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
BRPI0417543A (pt) 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
PT1784396E (pt) * 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
CA2617056A1 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
EA201300320A1 (ru) * 2005-09-07 2014-02-28 Эмджен Фримонт Инк. Моноклональные антитела человека к киназе-1, подобной рецептору активина
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009001715A (es) 2006-08-21 2009-02-25 Hoffmann La Roche Terapia tumoral con un anticuerpo anti-vegf.
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (de) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
WO2011093365A1 (ja) * 2010-01-27 2011-08-04 協和発酵キリン株式会社 含窒素複素環化合物
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
AU2013331505A1 (en) 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
CA2888210C (en) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3057422B1 (de) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Chinolinylmodulatoren von ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2024137751A1 (en) * 2022-12-21 2024-06-27 Kura Oncology, Inc. Methods of treating advanced solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
DE69807222T2 (de) * 1997-06-02 2003-04-17 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
BR9911869A (pt) * 1998-07-06 2001-03-27 Janssen Pharmaceutica Nv Inibidores da transferase da proteìna farnesil para o tratamento das artropatias
CN1340051A (zh) * 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物

Also Published As

Publication number Publication date
JP2001213876A (ja) 2001-08-07
PT1106612E (pt) 2004-06-30
BR0005633A (pt) 2001-07-17
ES2212971T3 (es) 2004-08-16
TR200400342T4 (tr) 2004-03-22
EP1106612A1 (de) 2001-06-13
MXPA00011856A (es) 2002-06-04
US6596735B1 (en) 2003-07-22
EP1106612B1 (de) 2004-02-11
ATE259365T1 (de) 2004-02-15
DE60008206T2 (de) 2004-12-02
DE60008206D1 (de) 2004-03-18
CA2327026A1 (en) 2001-05-30

Similar Documents

Publication Publication Date Title
DK1106612T3 (da) Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
EP1156045A4 (de) Amid-derivate und drogen-zusammensetzungen
ATE242231T1 (de) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
DK0418845T3 (da) Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme
DE69710319D1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
DK0657458T3 (da) Inhibitorer af proteinkinase-C
ES2185635T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
HUP0101146A2 (hu) Foszfolipáz enzim inhibitor hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyászati készítmények
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
DK1265606T3 (da) Celleadhæsionsinhibitorer
PT928788E (pt) Compostos farmaceuticamente activos
PT992509E (pt) Novos derivados macrolidos
HUP0102981A2 (hu) Pirrolo[1,2-a]pirazin-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0004142A2 (hu) 5-HT1F agonista hatású karboxamidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
PT1351954E (pt) Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
AU2003251172A1 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
BR9908948A (pt) Composição farmacêutica contendo um inibidor de protease cisteìna para profilaxia e terapia de dano ao tecido cerebral
EA200300009A1 (ru) Производные 4,5-дигидротиазол-2-иламина и их применение в качестве ингибиторов no синтазы
HUP0202237A2 (hu) Amin, módosított pszeudomicin vegyületek, azokat tartalmazó gyógyászati készítmény és alkalmazásuk